Baertsch, Marc-Andrea, Schlenzka, Jana, Lisenko, Katharina, Krzykalla, Julia, Becker, Natalia, Weisel, Katja, Noppeney, Richard, Martin, Hans, Lindemann, Hans W., Haenel, Mathias, Nogai, Axel, Scheid, Christof, Salwender, Hans ORCID: 0000-0001-7803-0814, Fenk, Roland, Graeven, Ullrich, Reimer, Peter, Schmidt-Hieber, Martin, Goerner, Martin, Schmidt-Wolf, Ingo G. H., Klein, Stefan, Ho, Anthony D., Goldschmidt, Hartmut and Wuchter, Patrick (2017). Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. Eur. J. Haematol., 99 (1). S. 42 - 51. HOBOKEN: WILEY. ISSN 1600-0609

Full text not available from this repository.

Abstract

ObjectiveAnalysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM). MethodsPeripheral blood stem cells (PBSCs) were mobilized with high dose cyclophosphamide (2g/m(2) daily on days 1 and 2) and G-CSF plus pre-emptive/rescue plerixafor in RMM patients (first to third relapse) treated within the ReLApsE trial of the German-Speaking Myeloma Multicenter Group (GMMG). ResultsMobilization was initiated with high-dose cyclophosphamide (HD-CY) and G-CSF in 30 patients. Fifteen patients received additional pre-emptive/rescue administration of plerixafor. Stem cell collection was successful (2x10(6) CD34+ cells per kgbw) in 77% (23/30 patients). Patients with prior high-dose melphalan collected a significantly lower median total number of PBSCs than patients without prior high-dose melphalan (3.3x10(6) vs 17x10(6) CD34+ cells/kgbw). Toxicity of HD-CY was frequent with 12 serious adverse events (SAE) in 37% of patients (11/30 patients). Infections accounted for the majority of SAE reports. In two patients, SAEs were lethal (septic shock). ConclusionsThese data proof feasibility of PBSC collection at relapse but emphasize the importance of collection and storage of additional PBSC transplants during first-line treatment when mobilization is more efficient and less toxic.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Baertsch, Marc-AndreaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schlenzka, JanaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lisenko, KatharinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krzykalla, JuliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Becker, NataliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weisel, KatjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Noppeney, RichardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Martin, HansUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lindemann, Hans W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haenel, MathiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nogai, AxelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Salwender, HansUNSPECIFIEDorcid.org/0000-0001-7803-0814UNSPECIFIED
Fenk, RolandUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Graeven, UllrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reimer, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmidt-Hieber, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goerner, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmidt-Wolf, Ingo G. H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klein, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ho, Anthony D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goldschmidt, HartmutUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wuchter, PatrickUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-226354
DOI: 10.1111/ejh.12888
Journal or Publication Title: Eur. J. Haematol.
Volume: 99
Number: 1
Page Range: S. 42 - 51
Date: 2017
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1600-0609
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
HIGH-DOSE CYCLOPHOSPHAMIDE; COLONY-STIMULATING FACTOR; BLOOD PROGENITOR CELLS; G-CSF; AUTOLOGOUS TRANSPLANTATION; LENALIDOMIDE THERAPY; INTENSIVE TRIAL; PLERIXAFOR; COLLECTION; LYMPHOMAMultiple languages
HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/22635

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item